Maxcyte Stock Price To Book

MXCT Stock

USD 3.55 0.10 2.90%

MaxCyte fundamentals help investors to digest information that contributes to MaxCyte's financial success or failures. It also enables traders to predict the movement of MaxCyte Stock. The fundamental analysis module provides a way to measure MaxCyte's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MaxCyte stock.

Short Long Term Debt Total Total Assets

Price To Book Ratio is likely to gain to 2.20 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

MaxCyte Company Price To Book Analysis

MaxCyte's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Current MaxCyte Price To Book

1.76 X

Most of MaxCyte's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MaxCyte is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

MaxCyte Price To Book Driver Correlations

Understanding the fundamental principles of building solid financial models for MaxCyte is extremely important. It helps to project a fair market value of MaxCyte Stock properly, considering its historical fundamentals such as Price To Book. Since MaxCyte's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MaxCyte's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MaxCyte's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Long Term Debt	Net Invested Capital	Short Long Term Debt	Net Working Capital	Property Plant Equipment	Short Term Investments	Capital Stock	Capital Surpluse
Total Assets		1.0	0.83	-0.64	-0.92	-0.4	0.8	0.91	0.99	-0.38	0.79	0.99	0.76	0.95	-0.6	0.94	0.94	0.94	0.96	0.69
Total Stockholder Equity	1.0		0.83	-0.64	-0.9	-0.4	0.79	0.89	0.99	-0.37	0.78	0.99	0.74	0.96	-0.58	0.95	0.93	0.95	0.96	0.67
Current Deferred Revenue	0.83	0.83		-0.57	-0.81	-0.2	0.93	0.8	0.87	-0.59	0.94	0.75	0.74	0.85	-0.21	0.85	0.73	0.86	0.9	0.39
Net Debt	-0.64	-0.64	-0.57		0.64	-0.1	-0.37	-0.57	-0.63	0.25	-0.65	-0.63	-0.59	-0.57	0.49	-0.55	-0.52	-0.51	-0.61	-0.46
Retained Earnings	-0.92	-0.9	-0.81	0.64		0.32	-0.77	-0.99	-0.86	0.36	-0.84	-0.91	-0.91	-0.8	0.71	-0.75	-0.96	-0.76	-0.91	-0.81
Accounts Payable	-0.4	-0.4	-0.2	-0.1	0.32		-0.15	-0.31	-0.36	0.02	-0.05	-0.45	-0.22	-0.41	0.32	-0.39	-0.49	-0.4	-0.49	-0.38
Net Receivables	0.8	0.79	0.93	-0.37	-0.77	-0.15		0.78	0.83	-0.47	0.9	0.7	0.7	0.8	-0.17	0.81	0.71	0.84	0.83	0.35
Total Liab	0.91	0.89	0.8	-0.57	-0.99	-0.31	0.78		0.85	-0.43	0.82	0.9	0.86	0.78	-0.71	0.74	0.96	0.76	0.89	0.79
Total Current Assets	0.99	0.99	0.87	-0.63	-0.86	-0.36	0.83	0.85		-0.42	0.81	0.96	0.7	0.97	-0.48	0.97	0.88	0.98	0.96	0.57
Short Term Debt	-0.38	-0.37	-0.59	0.25	0.36	0.02	-0.47	-0.43	-0.42		-0.5	-0.3	-0.11	-0.35	0.03	-0.39	-0.3	-0.41	-0.39	0.01
Common Stock	0.79	0.78	0.94	-0.65	-0.84	-0.05	0.9	0.82	0.81	-0.5		0.71	0.81	0.78	-0.26	0.76	0.72	0.76	0.85	0.48
Net Tangible Assets	0.99	0.99	0.75	-0.63	-0.91	-0.45	0.7	0.9	0.96	-0.3	0.71		0.74	0.93	-0.68	0.9	0.95	0.9	0.94	0.76
Long Term Debt	0.76	0.74	0.74	-0.59	-0.91	-0.22	0.7	0.86	0.7	-0.11	0.81	0.74		0.66	-0.59	0.6	0.82	0.6	0.79	0.73
Net Invested Capital	0.95	0.96	0.85	-0.57	-0.8	-0.41	0.8	0.78	0.97	-0.35	0.78	0.93	0.66		-0.36	0.99	0.84	0.98	0.95	0.58
Short Long Term Debt	-0.6	-0.58	-0.21	0.49	0.71	0.32	-0.17	-0.71	-0.48	0.03	-0.26	-0.68	-0.59	-0.36		-0.31	-0.75	-0.31	-0.5	-0.82
Net Working Capital	0.94	0.95	0.85	-0.55	-0.75	-0.39	0.81	0.74	0.97	-0.39	0.76	0.9	0.6	0.99	-0.31		0.79	0.99	0.93	0.48
Property Plant Equipment	0.94	0.93	0.73	-0.52	-0.96	-0.49	0.71	0.96	0.88	-0.3	0.72	0.95	0.82	0.84	-0.75	0.79		0.8	0.91	0.84
Short Term Investments	0.94	0.95	0.86	-0.51	-0.76	-0.4	0.84	0.76	0.98	-0.41	0.76	0.9	0.6	0.98	-0.31	0.99	0.8		0.92	0.46
Capital Stock	0.96	0.96	0.9	-0.61	-0.91	-0.49	0.83	0.89	0.96	-0.39	0.85	0.94	0.79	0.95	-0.5	0.93	0.91	0.92		0.66
Capital Surpluse	0.69	0.67	0.39	-0.46	-0.81	-0.38	0.35	0.79	0.57	0.01	0.48	0.76	0.73	0.58	-0.82	0.48	0.84	0.46	0.66

Click cells to compare fundamentals

Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Competition

Predict MaxCyte

Price Book Value Ratio Over Time

MaxCyte Book Value Per Share

Book Value Per Share

2.36

At this time, MaxCyte's Book Value Per Share is comparatively stable compared to the past year.

Based on the latest financial disclosure, MaxCyte has a Price To Book of 1.7556 times. This is 93.16% lower than that of the Health Care Equipment & Supplies sector and 69.04% lower than that of the Health Care industry. The price to book for all United States stocks is 81.54% higher than that of the company.

MaxCyte Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MaxCyte's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MaxCyte could also be used in its relative valuation, which is a method of valuing MaxCyte by comparing valuation metrics of similar companies.

MaxCyte is currently under evaluation in price to book category among its peers.

MaxCyte ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, MaxCyte's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to MaxCyte's managers, analysts, and investors.

Environmental

Governance

Social

MaxCyte Fundamentals

	Return On Equity	-0.16
	Return On Asset	-0.11
	Profit Margin	(0.78) %
	Operating Margin	(1.72) %
	Current Valuation	224.2 M
	Shares Outstanding	105.48 M
	Shares Owned By Insiders	1.49 %
	Shares Owned By Institutions	70.51 %
	Number Of Shares Shorted	3.24 M
	Price To Book	1.76 X
	Price To Sales	8.21 X
	Revenue	41.29 M
	Gross Profit	39.16 M
	EBITDA	(44.13 M)
	Net Income	(37.92 M)
	Cash And Equivalents	240.89 M
	Cash Per Share	2.37 X
	Total Debt	18.74 M
	Debt To Equity	0.06 %
	Current Ratio	14.24 X
	Book Value Per Share	2.03 X
	Cash Flow From Operations	(21.69 M)
	Short Ratio	11.38 X
	Earnings Per Share	(0.34) X
	Target Price	9.25
	Number Of Employees	143
	Beta	1.16
	Market Capitalization	374.46 M
	Total Asset	268.27 M
	Retained Earnings	(175.8 M)
	Working Capital	172.34 M
	Net Asset	268.27 M

About MaxCyte Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze MaxCyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MaxCyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MaxCyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for MaxCyte Stock Analysis

When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC